News Archive

January 2018

• Press Release Jan 16, 2018

  AveXis Announces Pricing of Public Offering of Common Stock

  CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,921,600 shares of its common stock at a public offering…
• Press Release Jan 16, 2018

  AveXis Announces Proposed Public Offering of Common Stock

  CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its…
• Press Release Jan 16, 2018

  AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

  – Company to expand study of AVXS-101 into additional SMA populations including pre-symptomatic, older pediatric Type 2 and Type 3 SMA patients – – First patient dosed in Phase 1 trial of…
• Press Release Jan 16, 2018

  Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients

  Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1]…
• Press Release Jan 16, 2018

  Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA

  Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1] The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab…
• Key Release Jan 11, 2018

  Novartis appoints Elizabeth Barrett as Oncology Head

  Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development…
• Key Release Jan 11, 2018

  Novartis ernennt Elizabeth Barrett zur Chefin Onkologie

  Novartis ernennt eine erfahrene Pharma-Führungskraft mit starken Marketingfähigkeiten, um das Onkologiegeschäft weiter zu entwickeln Novartis ernennt ad interim Leiter für die Global Drug…
• Press Release Jan 09, 2018

  Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

  SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED is the first head-to-head superiority trial…
• Press Release Jan 08, 2018

  REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

  AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA Amended agreement permits assignment by AveXis upon a change of control…
• 
  Story Jan 06, 2018 Discovery

  Organic dealmaker for drug discovery

  New Global Head of Business Development and Licensing for research makes connections naturally, decisions scientifically.

• 
  Story Jan 06, 2018 Discovery

  Open science demystified

  Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

• Press Release Jan 04, 2018

  AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1

  – Company to submit information requested by FDA to the IND on an on-going basis – – AveXis plans to request a pre-BLA meeting in Q2 2018 – – Conference call and webcast today at 4:…